TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · IEX Real-Time Price · USD
15.88
+2.22 (16.25%)
At close: May 1, 2024, 4:00 PM
15.97
+0.09 (0.57%)
Pre-market: May 2, 2024, 7:00 AM EDT
TG Therapeutics Employees
TG Therapeutics had 264 employees on December 31, 2023. The number of employees increased by 38 or 16.81% compared to the previous year.
Employees
264
Change (1Y)
38
Growth (1Y)
16.81%
Revenue / Employee
$885,083
Profits / Employee
$48,000
Market Cap
2.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 264 | 38 | 16.81% |
Dec 31, 2022 | 226 | -60 | -20.98% |
Dec 31, 2021 | 286 | 14 | 5.15% |
Dec 31, 2020 | 272 | 138 | 102.99% |
Dec 31, 2019 | 134 | 29 | 27.62% |
Dec 31, 2018 | 105 | 30 | 40.00% |
Dec 31, 2017 | 75 | 11 | 17.19% |
Dec 31, 2016 | 64 | 24 | 60.00% |
Dec 31, 2015 | 40 | 16 | 66.67% |
Dec 31, 2014 | 24 | 11 | 84.62% |
Dec 31, 2013 | 13 | 7 | 116.67% |
Dec 31, 2012 | 6 | 1 | 20.00% |
Dec 31, 2011 | 5 | 3 | 150.00% |
Dec 31, 2010 | 2 | -2 | -50.00% |
Dec 31, 2009 | 4 | 0 | - |
Dec 31, 2008 | 4 | -3 | -42.86% |
Dec 31, 2007 | 7 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
ICU Medical | 14,000 |
LifeStance Health Group | 9,325 |
Premier | 2,800 |
Tandem Diabetes Care | 2,400 |
Inari Medical | 1,300 |
Indivior | 1,164 |
Corcept Therapeutics | 352 |
Rhythm Pharmaceuticals | 226 |
TGTX News
- 21 hours ago - TG Therapeutics stock just rallied 30%: what happened? - Invezz
- 1 day ago - TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 1 day ago - TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 13 days ago - TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 14 days ago - TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis - GlobeNewsWire
- 16 days ago - TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 5 weeks ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 7 weeks ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire